Tanvex's US Unit Receives FDA Nod for TX05 Cancer Drug Biosimilar; Shares Drop 10%
MT Newswires Live
Jun 25
Tanvex Biopharma's (TPE:6541) US unit received a Complete Response Letter (CRL) from the US Food and Drug Administration for the biologics license application of TX05, a biosimilar to Herceptin used to treat breast and gastric cancers.
Shares slumped about 10% in Thursday's late afternoon trade.
The FDA's comments relate to issues at a third-party downstream manufacturing facility, while no concerns were raised regarding the drug substance produced by Tanvex, the pharmaceutical company said.
Tanvex is working with the contract manufacturer to address the issues and expects to resubmit the application by the end of July, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.